Home
Live Updates
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma : comparemela.com
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® using PD-L1 IHC 22C3 pharmDx
...
Related Keywords
United States ,
Canada ,
Lou Welebob ,
Biochem Pharmacol ,
Prz Gastroenterol ,
Merck Co Inc ,
Agilent Pathology Division ,
Merck Sharp Dohme ,
Agilent Technologies Inc ,
Agilent Technologies ,
Facebook ,
Gastroesophageal Junction ,
Pathology Division ,
Merck Sharp ,
End Results ,
Targeted Therapy ,
Advanced Gastric ,
Markets ,
comparemela.com © 2020. All Rights Reserved.